These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
185 related items for PubMed ID: 15669881
1. Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection. Lyseng-Williamson KA, Reynolds NA, Plosker GL. Drugs; 2005; 65(3):413-32. PubMed ID: 15669881 [Abstract] [Full Text] [Related]
3. Efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Atripla®): a review of its use in the management of HIV infection. Deeks ED, Perry CM. Drugs; 2010 Dec 03; 70(17):2315-38. PubMed ID: 21080746 [Abstract] [Full Text] [Related]
4. Tenofovir disoproxil fumarate (Viread) for the treatment of HIV infection. Gallant JE, Pham PA. Expert Rev Anti Infect Ther; 2003 Oct 03; 1(3):415-22. PubMed ID: 15482138 [Abstract] [Full Text] [Related]
7. Patterns of resistance emerging in HIV-1 from antiretroviral-experienced patients undergoing intensification therapy with tenofovir disoproxil fumarate. McColl DJ, Margot NA, Wulfsohn M, Coakley DF, Cheng AK, Miller MD. J Acquir Immune Defic Syndr; 2004 Nov 01; 37(3):1340-50. PubMed ID: 15483463 [Abstract] [Full Text] [Related]
8. Emtricitabine/tenofovir disoproxil fumarate. Drugs R D; 2004 Nov 01; 5(3):160-1. PubMed ID: 15139777 [Abstract] [Full Text] [Related]
9. Tenofovir disoproxil fumarate: a nucleotide reverse transcriptase inhibitor for the treatment of HIV infection. Fung HB, Stone EA, Piacenti FJ. Clin Ther; 2002 Oct 01; 24(10):1515-48. PubMed ID: 12462284 [Abstract] [Full Text] [Related]
11. Tenofovir disoproxil fumarate. Grim SA, Romanelli F. Ann Pharmacother; 2003 Jun 01; 37(6):849-59. PubMed ID: 12773076 [Abstract] [Full Text] [Related]
12. Tenofovir disoproxil fumarate: in chronic hepatitis B. Perry CM, Simpson D. Drugs; 2009 Nov 12; 69(16):2245-56. PubMed ID: 19852527 [Abstract] [Full Text] [Related]
13. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection. Hazra R, Gafni RI, Maldarelli F, Balis FM, Tullio AN, DeCarlo E, Worrell CJ, Steinberg SM, Flaherty J, Yale K, Kearney BP, Zeichner SL. Pediatrics; 2005 Dec 12; 116(6):e846-54. PubMed ID: 16291735 [Abstract] [Full Text] [Related]
14. Assessment of drug-drug interactions between tenofovir disoproxil fumarate and the nonnucleoside reverse transcriptase inhibitors nevirapine and efavirenz in HIV-infected patients. Droste JA, Kearney BP, Hekster YA, Burger DM. J Acquir Immune Defic Syndr; 2006 Jan 01; 41(1):37-43. PubMed ID: 16340471 [Abstract] [Full Text] [Related]
18. Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children. Gafni RI, Hazra R, Reynolds JC, Maldarelli F, Tullio AN, DeCarlo E, Worrell CJ, Flaherty JF, Yale K, Kearney BP, Zeichner SL. Pediatrics; 2006 Sep 01; 118(3):e711-8. PubMed ID: 16923923 [Abstract] [Full Text] [Related]
19. Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics. Kearney BP, Flaherty JF, Shah J. Clin Pharmacokinet; 2004 Sep 01; 43(9):595-612. PubMed ID: 15217303 [Abstract] [Full Text] [Related]